Read more

July 27, 2023
6 min watch
Save

VIDEO: New treatment options, recommendations for alopecia areata

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this Healio video exclusive, George Martin, MD, discusses highlights from Maui Derm NP+PA, including recent approvals and new treatments for alopecia areata.

“Fight for your patients with alopecia areata to get baricitinib,” Martin, program director of Maui Derm, said.

He further noted that some insurance carriers reject the treatment, classifying alopecia areata as a cosmetic disease.

“About a third of patients with a once-daily dosing [of baricitinib] achieve a SALT score of 80, which means 80% of hair regrowth. Phenomenal," Martin said.

Discussing ritlecitinib, the Janus kinase 3 and tyrosine kinase inhibitor, Martin noted that the SALT scores were comparable with baricitinib.

“Highly effective, very safe, 50 mg once a day, 12 years and older,” he said.

In addition, Martin discussed recommendations for administration of photodynamic therapy.